The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

As­traZeneca paid a hefty price to part­ner with Dai­ichi Sankyo on their ex­per­i­men­tal an­ti­body drug con­ju­gate for HER2 pos­i­tive breast can­cer. And they’ve been re­ward­ed with a fast ride through the FDA, with a straight shot at cre­at­ing an­oth­er block­buster on­col­o­gy fran­chise.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN